Risk of complications and mortality following recurrent and non-recurrent Clostridioides difficile infection: a retrospective, observational, database study in England.
BACKGROUND: Clostridioides difficile infection (CDI) increases the risk of complications and mortality. We assessed the magnitude of these outcomes in a large cohort of English patients with initial and recurrent CDI.
AIM: To compare the risk of complications and all-cause mortality, within 12 months, among hospitalized patients >/=18 years old with hospital-associated (HA-) CDI and recurrent CDI.
METHODS: Patients with HA-CDI during 2002-2013 were identified using inpatient hospital data linked to primary care and death data. Each HA-CDI case was frequency matched to two hospitalized patients without CDI on age group, sex, calendar year of admission, admission method and number of hospital care episodes. A second CDI episode starting on Days 13-56 was defined as recurrence. Risks of mortality and complications at 12 months were analysed using Cox proportional hazard models.
FINDINGS: We included 6,862 patients with HA-CDI and 13,724 without CDI. Median age was 81.0 (71.0-87.0). Patients with HA-CDI had more comorbidities than those without CDI, and significantly higher risks of mortality (adjusted hazard ratio (95% confidence interval) 1.77 (1.67-1.87)) and complications (1.66 (1.46-1.88)) within 12 months from hospital admission. Of those with HA-CDI, 1,140 (16.6%) experienced CDI recurrence. Patients with recurrent versus non-recurrent CDI also had significantly increased risk of mortality (1.32 (1.20-1.45)) and complications (1.37 (1.01-1.84)) in the 12 months from the initial CDI.
CONCLUSIONS: HA-CDI (versus no CDI) and recurrent CDI are both associated with significantly higher risks of complications or death within 12 months of the initial CDI episode.
|ジャーナル名||The Journal of hospital infection|
|投稿者||Enoch, David A; Murray-Thomas, Tarita; Adomakoh, Nicholas; Dedman, Daniel; Georgopali, Areti; Francis, Nick; Karas, Andreas|
|組織名||Public Health England, Addenbrooke's Hospital, Cambridge, UK. Electronic address:;email@example.com.;Clinical Practice Research Datalink, London, UK.;Astellas Pharma Europe Ltd, Chertsey, UK.;Division of Population Medicine, Cardiff University, Cardiff, UK; Current;affiliation: School of Primary Care, Population Sciences and Medical Education,;University of Southampton, UK.|